{"title":"美国超说明书用药和禁忌症用药的流行程度及其与健康的关系:一项横断面研究","authors":"Katharina E Blankart, Frank R Lichtenberg","doi":"10.1080/20523211.2025.2472221","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Off-label and contraindicated prescription drug use can result in adverse health outcomes. Despite concerns, the extent and characteristics of such usage patterns remain underexplored in the American population. We conducted a cross-sectional study analysing outpatient prescription data between 2016 and 2021 to determine the prevalence of off-label and contraindicated drug use.</p><p><strong>Methods: </strong>The study used labelling information from DrugCentral and the Medical Expenditure Panel Survey, focusing on the American non-institutionalised population. We analysed 9872 drug-indication and 34,138 drug-contraindication pairs among 46,770 patients and 1,596,753 prescriptions. Linear and probit regressions, and a double machine learning approach, were employed to assess associations between off-label/contraindicated use, health status, and healthcare utilisation, adjusting for demographic and health-related factors.</p><p><strong>Results: </strong>Overall, 75% of prescriptions were for labelled indications, while 25% were off-label; 54% were contraindicated. Only 33% of prescriptions were both indicated and not contraindicated. Off-label prescriptions had a lower contraindication rate (48.8%) compared to indicated prescriptions (56.2%). Improved health status and reduced medical expenditure correlated with lower off-label prescription rates. Notably, newer drugs (post-1997) had a higher rate of prescriptions that were both indicated and not contraindicated (43%) compared to older drugs (pre-1979, 21%). Patterns of off-label and contraindicated use were consistent across racial and educational demographics.</p><p><strong>Conclusion: </strong>Off-label and contraindicated drug use is prevalent in outpatient prescriptions and is associated with worse health outcomes and increased healthcare utilisation. These findings suggest a need for enhanced monitoring and regulatory measures to minimise risks associated with inappropriate prescription practices.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2472221"},"PeriodicalIF":3.3000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892052/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prevalence and relationship with health of off-label and contraindicated drug use in the United States: a cross-sectional study.\",\"authors\":\"Katharina E Blankart, Frank R Lichtenberg\",\"doi\":\"10.1080/20523211.2025.2472221\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Off-label and contraindicated prescription drug use can result in adverse health outcomes. Despite concerns, the extent and characteristics of such usage patterns remain underexplored in the American population. We conducted a cross-sectional study analysing outpatient prescription data between 2016 and 2021 to determine the prevalence of off-label and contraindicated drug use.</p><p><strong>Methods: </strong>The study used labelling information from DrugCentral and the Medical Expenditure Panel Survey, focusing on the American non-institutionalised population. We analysed 9872 drug-indication and 34,138 drug-contraindication pairs among 46,770 patients and 1,596,753 prescriptions. Linear and probit regressions, and a double machine learning approach, were employed to assess associations between off-label/contraindicated use, health status, and healthcare utilisation, adjusting for demographic and health-related factors.</p><p><strong>Results: </strong>Overall, 75% of prescriptions were for labelled indications, while 25% were off-label; 54% were contraindicated. Only 33% of prescriptions were both indicated and not contraindicated. Off-label prescriptions had a lower contraindication rate (48.8%) compared to indicated prescriptions (56.2%). Improved health status and reduced medical expenditure correlated with lower off-label prescription rates. Notably, newer drugs (post-1997) had a higher rate of prescriptions that were both indicated and not contraindicated (43%) compared to older drugs (pre-1979, 21%). Patterns of off-label and contraindicated use were consistent across racial and educational demographics.</p><p><strong>Conclusion: </strong>Off-label and contraindicated drug use is prevalent in outpatient prescriptions and is associated with worse health outcomes and increased healthcare utilisation. These findings suggest a need for enhanced monitoring and regulatory measures to minimise risks associated with inappropriate prescription practices.</p>\",\"PeriodicalId\":16740,\"journal\":{\"name\":\"Journal of Pharmaceutical Policy and Practice\",\"volume\":\"18 1\",\"pages\":\"2472221\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-03-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892052/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmaceutical Policy and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/20523211.2025.2472221\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"HEALTH POLICY & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20523211.2025.2472221","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
Prevalence and relationship with health of off-label and contraindicated drug use in the United States: a cross-sectional study.
Background: Off-label and contraindicated prescription drug use can result in adverse health outcomes. Despite concerns, the extent and characteristics of such usage patterns remain underexplored in the American population. We conducted a cross-sectional study analysing outpatient prescription data between 2016 and 2021 to determine the prevalence of off-label and contraindicated drug use.
Methods: The study used labelling information from DrugCentral and the Medical Expenditure Panel Survey, focusing on the American non-institutionalised population. We analysed 9872 drug-indication and 34,138 drug-contraindication pairs among 46,770 patients and 1,596,753 prescriptions. Linear and probit regressions, and a double machine learning approach, were employed to assess associations between off-label/contraindicated use, health status, and healthcare utilisation, adjusting for demographic and health-related factors.
Results: Overall, 75% of prescriptions were for labelled indications, while 25% were off-label; 54% were contraindicated. Only 33% of prescriptions were both indicated and not contraindicated. Off-label prescriptions had a lower contraindication rate (48.8%) compared to indicated prescriptions (56.2%). Improved health status and reduced medical expenditure correlated with lower off-label prescription rates. Notably, newer drugs (post-1997) had a higher rate of prescriptions that were both indicated and not contraindicated (43%) compared to older drugs (pre-1979, 21%). Patterns of off-label and contraindicated use were consistent across racial and educational demographics.
Conclusion: Off-label and contraindicated drug use is prevalent in outpatient prescriptions and is associated with worse health outcomes and increased healthcare utilisation. These findings suggest a need for enhanced monitoring and regulatory measures to minimise risks associated with inappropriate prescription practices.